Presented by: Lynette Schroeter-Tedesco and Jonathan Alvarez, Ajinomoto Althea
Presented Live: May 15, 2018
The Crystalomics® Department at Ajinomoto Althea CMO uses crystallized biotherapeutics to develop high concentration, low viscosity injectable drug formulations exceeding 200 mg/mL. The first step in our technology is to discover and develop crystallization conditions as rapidly as possible in order to meet short development timelines.
Crystallization of proteins, especially monoclonal antibodies (mAbs), is very challenging and typically employs extensive trial-and-error. Incorporating high-throughput dynamic light scattering (HT-DLS) into our pre-crystallization screening to characterize the protein in multiple buffers, we are able to significantly reduce the extent of crystallization trials. Analysis of the mAbs by multi-angle light scattering coupled to size-exclusion chromatography (SEC-MALS) as well as HT-DLS is critical to determining optimal crystallization conditions with minimal time and effort.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.